Literature DB >> 18759343

Subthalamic nucleus stimulation restores corticospinal facilitation in Parkinson's disease.

Monika Pötter-Nerger1, Tihomir V Ilic, Hartwiq R Siebner, Günther Deuschl, Jens Volkmann.   

Abstract

We have previously shown that in patients with Parkinson's disease (PD), high-frequency stimulation (HFS) of the subthalamic nucleus (STN) modifies spinal excitability via subcortical reticulospinal routes. To investigate whether STN-HFS also modifies spinal excitability via transcortical routes in PD, 10 patients with PD (9 men, 1 woman; 58.3 +/- 8.3 years) were investigated in the medical OFF-state with or without STN-HFS. The H-reflex of the right soleus muscle was recorded during slight plantar flexion at 20% of maximum force. A conditioning transcranial stimulus was applied at 95% of active motor threshold to the contralateral primary motor leg area (M1) 0-5 ms after eliciting the H-reflex. The same paradigm was applied to 8 healthy individuals (5 men, 3 women; 50.8 +/- 3.0 years). Transcranial magnetic stimulation (TMS) facilitated the H-reflex amplitude in healthy controls. A facilitatory effect of the corticospinal input on the H-reflex was also found in patients with PD, but only with STN-HFS switched on. When STN-HFS was discontinued, the H-reflex was no longer facilitated by the TMS pulse. Accordingly, analysis of variance showed a main effect of stimulation (F = 11.15; P = 0.005), ISI (F = 6.1; P = 0.003), and an interaction between stimulation and group (PD vs. control) (F = 8.9; P = 0.01). STN-HFS restores the normal facilitatory drive of a transcranially evoked motor cortical response to the spinal motoneuron pool. In addition to subcortical routes, STN-DBS also alters spinal excitability via transcortical pathways.

Entities:  

Mesh:

Year:  2008        PMID: 18759343     DOI: 10.1002/mds.22284

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  7 in total

1.  Subthalamic stimulation modulates cortical motor network activity and synchronization in Parkinson's disease.

Authors:  Daniel Weiss; Rosa Klotz; Rathinaswamy B Govindan; Marlieke Scholten; Georgios Naros; Ander Ramos-Murguialday; Friedemann Bunjes; Christoph Meisner; Christian Plewnia; Rejko Krüger; Alireza Gharabaghi
Journal:  Brain       Date:  2015-01-02       Impact factor: 13.501

Review 2.  Novel targets in deep brain stimulation for movement disorders.

Authors:  Alexander J Baumgartner; John A Thompson; Drew S Kern; Steven G Ojemann
Journal:  Neurosurg Rev       Date:  2022-05-05       Impact factor: 2.800

Review 3.  Safety of transcranial magnetic stimulation in Parkinson's disease: a review of the literature.

Authors:  Matthew Vonloh; Robert Chen; Benzi Kluger
Journal:  Parkinsonism Relat Disord       Date:  2013-03-07       Impact factor: 4.891

Review 4.  Postsynaptic nigrostriatal dopamine receptors and their role in movement regulation.

Authors:  Alexei Korchounov; Michael F Meyer; Michael Krasnianski
Journal:  J Neural Transm (Vienna)       Date:  2010-11-16       Impact factor: 3.575

5.  Tracing embodied word production in persons with Parkinson's disease in distinct motor conditions.

Authors:  Fabian Klostermann; Michelle Wyrobnik; Moritz Boll; Felicitas Ehlen; Hannes Ole Tiedt
Journal:  Sci Rep       Date:  2022-10-05       Impact factor: 4.996

6.  Nigral stimulation for resistant axial motor impairment in Parkinson's disease? A randomized controlled trial.

Authors:  Daniel Weiss; Margarete Walach; Christoph Meisner; Melanie Fritz; Marlieke Scholten; Sorin Breit; Christian Plewnia; Benjamin Bender; Alireza Gharabaghi; Tobias Wächter; Rejko Krüger
Journal:  Brain       Date:  2013-06-11       Impact factor: 13.501

7.  Anodal tDCS modulates cortical activity and synchronization in Parkinson's disease depending on motor processing.

Authors:  Anna Schoellmann; Marlieke Scholten; Barbara Wasserka; Rathinaswamy B Govindan; Rejko Krüger; Alireza Gharabaghi; Christian Plewnia; Daniel Weiss
Journal:  Neuroimage Clin       Date:  2019-01-23       Impact factor: 4.881

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.